MEA Diabetes Market

• Changing lifestyles is driving the market growth

Market CAGR for Middle East and Africa diabetes market is being grown due to continuous changing lifestyles. The prevalence of diabetes has alarmingly increased in recent years throughout the Middle East and Africa. Diabetes rates are at an all-time high, mostly as a result of lifestyle modifications. The primary motive of diabetes treatment is to keep blood glucose levels in a proper range in order to avoid both immediate and long-term problems such as heart disease, kidney disease, blindness, and lower limb amputation.

IDF 2021 reported that 73 million adults in the MENA region have diabetes. 95 million people are anticipated to be added to this number by 2030. Impaired glucose tolerance affects 48 million adults in the IDF MENA Region, putting them at higher risk of type 2 diabetes.

Furthermore, In July 2022, The sale of tablets containing metformin hydrochloride and empagliflozin in a variety of strengths has been officially approved, according to a statement from Zydus Lifesciences. To enhance glycemic control in persons with type-2 diabetes mellitus, empagliflozin and metformin hydrochloride tablets are used in accordance with a healthy diet and exercise.

Governments in the Middle East have recognized the threat that diabetes poses and have begun to take action with a number of policies, projects, and programs. National guidelines for the treatment of diabetes have been adopted in the majority of nations. In this region, there are still six of the fifteen nations without a national operational action plan for diabetes. Nevertheless, ongoing efforts are made to reduce diabetic complications.

It is predicted that the market will expand in the future because of the rising prevalence of type-2 diabetes, the rising prevalence of obesity, and the growing hereditary risk factors for the disease. Thus, driving the Middle East and Africa Diabetes market revenue.

The Global Middle East and Africa Diabetes Market Industry is projected to experience substantial growth in the coming years. With a current valuation of 25.67 USD Billion in 2024, the market is expected to reach 56.78 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 7.48% from 2025 to 2035. Such projections indicate a robust demand for diabetes care solutions, driven by increasing prevalence, technological advancements, and government initiatives. The market's expansion reflects the urgent need for comprehensive diabetes management strategies in the region.

The Global Middle East and Africa Diabetes Market Industry is experiencing a surge in diabetes cases, driven by lifestyle changes and urbanization. In 2024, the market is valued at 25.67 USD Billion, reflecting the growing health crisis. Factors such as sedentary lifestyles, unhealthy diets, and increasing obesity rates contribute to this trend. For instance, the International Diabetes Federation reports that the prevalence of diabetes in the Middle East and Africa is projected to rise significantly, indicating a pressing need for effective management solutions. This escalating prevalence underscores the urgency for healthcare systems to adapt and innovate.

Awareness and education regarding diabetes are crucial drivers of the Global Middle East and Africa Diabetes Market Industry. As public knowledge about diabetes increases, individuals are more likely to seek early diagnosis and treatment. Educational campaigns, often spearheaded by health organizations, aim to inform communities about risk factors and management strategies. This heightened awareness can lead to earlier interventions, reducing the long-term impact of the disease. Consequently, the market is likely to see growth as more individuals engage with healthcare services, fostering a proactive approach to diabetes management.

The Global Middle East and Africa Diabetes Market Industry is bolstered by rising healthcare expenditure in the region. Governments and private sectors are allocating more resources to combat diabetes, recognizing its economic burden. Increased funding for diabetes research, treatment facilities, and patient education programs reflects a commitment to addressing this health challenge. As healthcare spending rises, it is expected that the market will expand, driven by enhanced access to diabetes care and management services. This trend may lead to improved health outcomes and a reduction in diabetes-related complications, ultimately benefiting the overall healthcare system.

Government initiatives across the Middle East and Africa are pivotal in shaping the Global Middle East and Africa Diabetes Market Industry. Various countries are implementing policies aimed at enhancing diabetes awareness, prevention, and management. For example, national health programs are increasingly focusing on public education campaigns and subsidizing diabetes medications. These initiatives are likely to improve access to care and promote healthier lifestyles among populations. As governments invest in healthcare infrastructure, the market is expected to expand, potentially reaching a valuation of 56.78 USD Billion by 2035, reflecting the commitment to combat diabetes effectively.

Technological innovations are transforming the Global Middle East and Africa Diabetes Market Industry, offering new avenues for diabetes management. The advent of continuous glucose monitoring systems and insulin delivery devices enhances patient care and self-management capabilities. These advancements not only improve the quality of life for individuals with diabetes but also streamline healthcare delivery. As technology continues to evolve, it is anticipated that the market will witness a compound annual growth rate of 7.48% from 2025 to 2035. This growth indicates a robust demand for innovative solutions that cater to the unique needs of the region's diabetic population.

By region, the study provides the market insights into Middle East and Africa. The Middle East and Africa Diabetes market area will dominate this market, owing to an increase in the genetic factors for type 2 diabetics patients. In addition, the growing awareness of the government will boost market growth in this region. The South Africa held the fastest growth while Latin American is anticipated to register the fastest CAGR over the projected period.

Figure 2 MIDDLE EAST AND AFRICA DIABETES MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

In South Africa, one in nine persons have diabetes, according to the IDF Diabetes Atlas 2021. Numerous health issues are related to diabetes. Diabetes patients must make several adjustments throughout the day to keep their blood glucose levels within acceptable ranges. For example, they may need to take additional insulin or consume more carbohydrates. To overcome both instant and long-term problems like cardiovascular disease, kidney disease, blindness, and lower limb amputation, diabetes treatment seeks to maintain optimum blood glucose levels.

As a result of the aforementioned factors, it is predicted that the South Africa Diabetes Market would expand during the course of the analysis.

The GCC diabetes market is expanding due to growing number of diabetic pateints in the region. Latin American nations have a high rate of diabetes prevalence. According to the International Diabetes Federation, throughout the past ten years, the percentage of persons in the GCC states who have diabetes has remained largely stable 18.7% in Saudi Arabia, 16.4% in the United Arab Emirates, and 19.5% in Qatar. Comparatively speaking, just 10.7% of Americans have diabetes.

Further, the major countries studied in the market report are South Africa, GCC, and Rest of MEA.

Leading market players are adopting various strategies to ensure product innovation and development, which will aid the Middle East and Africa Diabetes market, grow faster than ever. Market players are also undertaking a range of business strategies to grow their  footprint, with important market developments including new product developments, contracts & agreements, mergers & acquisitions, increased investments, & collaboration with other similar organizations. To expand and survive in a more competitive and rising market climate, Middle East and Africa Diabetes industry must offer cost-effective items.

Manufacturing locally to minimize capital requirements is one of the key business tactics used by manufacturers in the Middle East and Africa Diabetes industry to benefit clients and increase the market sector. In recent years, the Middle East and Africa Diabetes industry has offered some of the most significant advantages to medicine. Major players in the Middle East and Africa Diabetes market, including Abbott, Bayer AG, Becton Dickinson and Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Roche Diabetes Care, Inc., Sanofi Avnetis U.S.

LLC., Ypsomed, and others, are attempting to enhance market demand by investing in research and development operations.

Novartis AG (Novartis) is a healthcare firm which holds expertise in the development, and manufacture of prescription as well as over-the-counter medicines, along with products for eye care. In addition to others, it offers medicines for the treatment of solid tumors, immunological disorders, infections, cardiovascular illness, dermatological issues, neurological disorders, ophthalmic and respiratory diseases, cancer, and neurological disorders. Through Sandoz, the business provides biosimilars and generic medications. In March 2022, According to Novartis, Beovu® (brolucizumab) 6 mg has been authorised by the European Commission (EC) for the treatment of diabetic macular edoema (DME), which causes vision loss.

Beovu was first approved by the EC in 20203 for the treatment of wet age-related macular degeneration; this approval in DME is its second indication.

A wide variety of healthcare goods are discovered, developed, produced, and sold by Abbott Laboratories (Abbott), including branded generic medications, diagnostic tools and procedures, and infant, child, and adult nutritional supplements. The business also sells a range of medical devices, such as those for neuromodulation, electrophysiology, rhythm control, vascular and structural cardiac devices, and heart failure. The business also sells dietary supplements, minerals, and nutrition goods. In February 2022, To usher in a new era of comprehensive diabetes management care, Abbott announced new partnerships with important health-tech companies BeatO, Healthifyme, Pharmeasy, Sugar.fit, and Fitterfly.